Last updated: April 30, 2024
Sponsor: Shirley Ryan AbilityLab
Overall Status: Active - Recruiting
Phase
N/A
Condition
Multiple Sclerosis
Memory Loss
Neurologic Disorders
Treatment
Acute Intermittent Hypoxia
Sham-Acute Intermittent Hypoxia
Clinical Study ID
NCT06276634
STU00219535
R21HD108587
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnoses of relapsing form of MS (including relapsing-remitting MS andsecondary-progressive MS)
- Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
- Motor Functional System Scale (FSS) between 2-4
- Relapse free for at least 1 year
- Age ≥ 18 years and ≤ 75 years
- Safe to be scanned based on MRI questionnaire
- Participants using dalfampridine will be eligible if taking the same daily dose for atleast 2 months prior to screening
Exclusion
Exclusion Criteria:
- Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive ofacute cerebrovascular disease on baseline MRI scan
- Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
- History of epilepsy
- Chronic obstructive pulmonary disease
- Uncontrolled Sleep apnea
- Pregnancy
Study Design
Total Participants: 21
Treatment Group(s): 2
Primary Treatment: Acute Intermittent Hypoxia
Phase:
Study Start date:
April 30, 2024
Estimated Completion Date:
January 31, 2027
Study Description
Connect with a study center
Shirley Ryan AbilityLab
Chicago, Illinois 60611
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.